Canada: For Your Phase 3 Global Trial Expansion
Oncology continues to be the largest and fastest growing therapeutic area in the clinical trials market, and a market dominated…
Doubly Nimble: why you should open global P1 clinical trials in Canada on Day 1
With agility increasingly becoming the most important global driver of success, it’s worth noting that Canadian oncology research center Phase…
What’s Best for Your Phase III Clinical Study?
It’s worth your time to consider whether or not the commonly held belief that using a larger CRO for your…
Troubleshooting Underperforming Sites – Best Practices
It’s no surprise that an underperforming site can cause significant delays in meeting important accrual targets, data timelines, or study…
Special Report: What’s in Store for Global Clinical Trials in 2022 and Beyond?
The Global Clinical Trials Market was valued at $44.3B USD in 2020, and by 2028 is expected to reach $69.3B…
Your CRO’s Assignment Strategy for CRAs Matters!
Monitoring the progress of clinical research is fundamental to obtaining successful outcomes because it ensures that constraints to success are…
Lessons Learned Moving Forward – Audit Readiness & Remote Close-Out Visits
The COVID-19 pandemic has required the clinical research industry to find new and innovative ways to monitor investigative sites. Although…
Prime Location for Global Clinical Studies?
Canada is considered one of the most attractive places to live in the world, with a high quality of life,…
Why Not Canada for Your Phase 3 Global Trial Expansion?
Pre-pandemic oncology was both the largest and fastest growing therapeutic area in the clinical trials market. A key market trend…
Diversity in Clinical Trial Participants: Canada Holds Promise
Participant diversity in clinical trials can be quite challenging to achieve. With COVID the concern about appropriate demographic representation is…